1. Scrip
  2. >>Therapy Areas

Good News For Immunomedics' Triple Negative Breast Cancer Trial

 
• By Jessica Merrill

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Woman holding pink ribbon on wooden background. Cancer awareness concept
A Phase III trial in triple negative breast cancer was stopped early for efficacy • Source: Shutterstock

Immunomedics Inc. has a biologics licensing application (BLA) pending at the US Food and Drug Administration for the antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer – and now it appears to have positive Phase III data to back up the Phase II data used for the submission.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.